Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal; Correction

---
identifier: "/us/fr/2023-00390"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal; Correction"
title_number: 0
title_name: "Federal Register"
section_number: "2023-00390"
section_name: "Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal; Correction"
positive_law: false
currency: "2023-01-11"
last_updated: "2023-01-11"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2023-00390"
document_type: "notice"
publication_date: "2023-01-11"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
fr_citation: "88 FR 1599"
fr_volume: 88
docket_ids:
  - "Docket No. FDA-2018-N-3091"
fr_action: "Notice; correction."
---


#  Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal; Correction

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Notice; correction.

**SUMMARY:**

The Food and Drug Administration is correcting a notice entitled “Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal” that appeared in the *Federal Register* of December 13, 2022. The document announced the renewal of the  Cardiovascular and Renal Drugs Advisory Committee. The document was published with the incorrect docket number. This document corrects that error.

**FOR FURTHER INFORMATION CONTACT:**

Lisa Granger, Office of Policy, Planning, Legislation and International Affairs, Food and Drug Administration, 301-796-9115, *[email protected].*

**SUPPLEMENTARY INFORMATION:**

In the *Federal Register* of Tuesday, December 13, 2022 (87 FR 76197), in FR Doc. 2022-27014, on page 76197 the following correction is made:

1. On page 76197, in the first column of the header of the document, “Docket No. FDA-2022-N-3091” is corrected to read “Docket No. FDA-2018-N-3091”.

Dated: January 3, 2023.

Lauren K. Roth,

Associate Commissioner for Policy.